The JULI Registry--Hemp and Cannabis Observational Registry
JULI
The JUvaLIfe Registry
1 other identifier
observational
2,000
1 country
4
Brief Summary
The JuLi Registry seeks to fill some of the gaps associated with the clinical use of CBD (cannabidiol) and other cannabinoid formulations including THC and others. The overarching goal of this Registry is to rapidly advance research and understanding of the use of cannabis and hemp-based formulations, in the clinical community setting, when it is utilized to manage the symptoms of cancer treatment and other underlying health issues. These symptoms include nausea, neuropathy, and sleeplessness and chronic pain.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2021
Typical duration for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 24, 2021
CompletedFirst Posted
Study publicly available on registry
January 27, 2021
CompletedStudy Start
First participant enrolled
August 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 15, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 15, 2025
CompletedJuly 19, 2022
July 1, 2022
2.5 years
January 24, 2021
July 15, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Symptom Relief
Percentage of patients who obtain and report symptom relief, by symptom, condition and cannabis formulation
3 months
Reduction in reliance on Rx medications
Percentage of patients who report reduction or increase in use of Rx medications
3 months
Secondary Outcomes (1)
Reduction in reliance on OTC medications
3 months
Eligibility Criteria
All patients greater than or equal to 21 years of age who are seeking to use hemp-based or cannabis-based formulations to relieve symptoms associated with medical interventions or conditions
You may qualify if:
- years of age or older
- Have requested from and/or decided with their providers to try CBD (hemp-based) or other cannabis products to relieve one or more symptoms related to a medical diagnosis
- Consent to have their health data included in a Registry and participate in PRO (patient reported outcomes) surveys and data collection via a study app.
You may not qualify if:
- Patient pregnant
- Unwilling or unable to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Juva Lifelead
- Targeted Medical Educationcollaborator
Study Sites (4)
Precision Cancer Specialists
Los Gatos, California, 95032, United States
Justin Lo MD
San Jose, California, 95128, United States
Nashville Breast Center
Nashville, Tennessee, 37203, United States
Dallas Surgical Group
Dallas, Texas, 75231, United States
Related Publications (2)
Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018 Mar 13;19(3):833. doi: 10.3390/ijms19030833.
PMID: 29533978BACKGROUNDFreitas HR, Isaac AR, Malcher-Lopes R, Diaz BL, Trevenzoli IH, De Melo Reis RA. Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr Neurosci. 2018 Dec;21(10):695-714. doi: 10.1080/1028415X.2017.1347373. Epub 2017 Jul 7.
PMID: 28686542RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 24, 2021
First Posted
January 27, 2021
Study Start
August 1, 2021
Primary Completion
February 15, 2024
Study Completion
February 15, 2025
Last Updated
July 19, 2022
Record last verified: 2022-07